The stock of Agenus Incorporated (NASDAQ:AGEN) registered a decrease of 6.17% in short interest. AGEN’s total short interest was 6.54 million shares in September as published by FINRA. Its down 6.17% from 6.97M shares, reported previously. With 1.05 million shares average volume, it will take short sellers 6 days to cover their AGEN’s short positions. The short interest to Agenus Incorporated’s float is 8.86%. About 601,550 shares traded hands. Agenus Inc (NASDAQ:AGEN) has risen 125.61% since February 8, 2016 and is uptrending. It has outperformed by 109.13% the S&P500.
Agenus Inc. is an immuno-oncology company. The company has a market cap of $563.98 million. The Firm is engaged in discovering and developing treatments for patients with cancer. It currently has negative earnings. The Company’s approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage and AutoSynVax, and saponin vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
The institutional sentiment decreased to 0.8 in 2016 Q2. Its down 0.58, from 1.38 in 2016Q1. The ratio turned negative, as 15 funds sold all Agenus Inc shares owned while 26 reduced positions. 7 funds bought stakes while 26 increased positions. They now own 34.68 million shares or 5.72% less from 36.79 million shares in 2016Q1.
Rtw Investments Llc holds 3.36% of its portfolio in Agenus Inc for 2.43 million shares. Venbio Select Advisor Llc owns 3.10 million shares or 2.79% of their US portfolio. Moreover, Oracle Investment Management Inc has 1.75% invested in the company for 1.86 million shares. The New York-based Qvt Financial Lp has invested 1.03% in the stock. Cormorant Asset Management Llc, a Massachusetts-based fund reported 1.58 million shares.
Out of 3 analysts covering Agenus (NASDAQ:AGEN), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $15 is the highest target while $7 is the lowest. The $9.67 average target is 56.73% above today’s ($6.17) stock price. Agenus has been the topic of 5 analyst reports since October 27, 2015 according to StockzIntelligence Inc. Jefferies maintained the stock on July 29 with “Buy” rating.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.